Sugi Predict

Sugi Predict / Compounds / Diflucortolone Pivalate

Diflucortolone Pivalate

Diflucortolone Pivalate

SCHEMBL668256

C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@H]1C(=O)COC(=O)C(C)(C)C

nearest known ligand 0.81

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PGR P06401 9/20 0.81
▸ HIF1A Q16665 9/20 0.81
▸ AR P10275 8/20 0.81
▸ CYP3A4 P08684 6/20 0.81
▸ ADORA3 P0DMS8 3/20 0.81
▸ NR1I2 O75469 3/20 0.78
▸ HTR2B P41595 1/20 0.78
▸ NR3C1 P04150 6/20 0.56
▸ SMN1; SMN2 Q16637 3/20 0.56
▸ LMNA P02545 3/20 0.56
▸ ABCB11 O95342 2/20 0.56
▸ CHRM1 P11229 2/20 0.56
▸ ALDH1A1 P00352 3/20 0.54
▸ CYP1A2 P05177 1/20 0.54
▸ MAPT P10636 1/20 0.53
▸ RAB9A P51151 1/20 0.53
▸ MEN1 O00255 2/20 0.50
▸ KMT2A Q03164 2/20 0.50
▸ NR3C2 P08235 1/20 0.50
▸ ALOX15 P16050 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Diflucortolone Pivalate SCHEMBL668257 1.00 PGR (0.81) PGRHIF1AARCYP3A4ADORA3
SCHEMBL6650283 0.91 PGR (0.80) PGRHIF1AARCYP3A4ADORA3
SCHEMBL22171576 0.91 PGR (0.83) PGRHIF1AARCYP3A4ADORA3
Clocortolone Pivalate SCHEMBL13423591 0.90 PGR (1.00) PGRHIF1AARCYP3A4ADORA3
Clocortolone Pivalate SCHEMBL10052573 0.90 PGR (1.00) PGRHIF1AARCYP3A4ADORA3
Clocortolone Pivalate SCHEMBL32668843 0.90 PGR (1.00) PGRHIF1AARCYP3A4ADORA3
Clocortolone Pivalate SCHEMBL5120 0.90 PGR (1.00) PGRHIF1AARCYP3A4ADORA3
Clocortolone Pivalate SCHEMBL6834795 0.90 PGR (1.00) PGRHIF1AARCYP3A4ADORA3
SCHEMBL11243017 0.89 PGR (0.80) PGRHIF1AARCYP3A4ADORA3
Diflucortolone SCHEMBL22040571 0.88 PGR (1.00) PGRHIF1AARCYP3A4ADORA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230108050-A1 CXCL8 (INTERLEUKIN-8) ACTIVITY INHIBITOR AND CORTICOSTEROID COMBINATION AND PHARMACEUTICAL COMPOSITION AND USE THEREOF DOMPE' FARMACEUTICI SPA (IT) 2023-04-06 — — US claimed
EP-4106738-A1 CXCL8 (INTERLEUKIN-8) ACTIVITY INHIBITOR AND CORTICOSTEROID COMBINATION AND PHARMACEUTICAL COMPOSITION AND USE THEREOF Dompe' Farmaceutici SpA (IT) 2022-12-28 — — EP claimed
US-20110020414-A1 MOISTURIZING RETINOL COMPOSITION THE BEAU SKIN LLC 2011-01-27 — — US claimed
US-20100221245-A1 TOPICAL SKIN CARE COMPOSITION DERMADOCTOR, LLC 2010-09-02 — — US claimed
WO-1997015298-A1 COMBINATION OF LTD, RECEPTOR ANTAGONISTS WITH GLUCOCORTICOSTEROIDS BAYER AKTIENGESELLSCHAFT (DE) 1997-05-01 — — WO claimed
US-4427670-A CONTAINING CORTICOSTEROID, PHOSPHATIDE, AND BUTYLHYDROXYANISOLE, OR BUTYLHYDROXYTOLUENE MITSUBISHI CHEMICAL INDUSTRIES LIMITED (JP) 1984-01-24 — — US claimed
US-20240423907-A1 Improved Nasal Administration of Pharmaceutical Formulations CYRANO THERAPEUTICS, INC. 2024-12-26 — — US disclosed
EP-4460284-A1 IMPROVED NASAL ADMINISTRATION OF PHARMACEUTICAL FORMULATIONS Cyrano Therapeutics, Inc. (US) 2024-11-13 — — EP disclosed
CN-115484943-B Combination of CXCL8 (interleukin-8) activity inhibitor and corticosteroid, pharmaceutical composition and use thereof 导博药物公司 2024-03-29 — — CN disclosed
WO-2023133460-A1 IMPROVED NASAL ADMINISTRATION OF PHARMACEUTICAL FORMULATIONS CYRANO THERAPEUTICS, INC. (US) 2023-07-13 — — WO disclosed
US-20230108050-A1 CXCL8 (INTERLEUKIN-8) ACTIVITY INHIBITOR AND CORTICOSTEROID COMBINATION AND PHARMACEUTICAL COMPOSITION AND USE THEREOF DOMPE' FARMACEUTICI SPA (IT) 2023-04-06 — — US disclosed
EP-4106738-A1 CXCL8 (INTERLEUKIN-8) ACTIVITY INHIBITOR AND CORTICOSTEROID COMBINATION AND PHARMACEUTICAL COMPOSITION AND USE THEREOF Dompe' Farmaceutici SpA (IT) 2022-12-28 — — EP disclosed
CN-115484943-A Combination of CXCL8 (interleukin-8) activity inhibitor and corticosteroid, pharmaceutical composition and use thereof 导博药物公司 2022-12-16 — — CN disclosed
WO-1999030690-A1 ORAL DELIVERY FORMULATION AXIA THERAPEUTICS, INC. (US) 1999-06-24 — — WO disclosed
EP-0909183-A2 DHA-PHARMACEUTICAL AGENT CONJUGATES Neuromedica, Inc. (US) 1999-04-21 — — EP disclosed
US-5795909-A ANTICARCINOGENIC AND ANTITUMOR AGENTS; BREAST, COLON, OVARIANCANCERS NEUROMEDICA, INC. (US) 1998-08-18 — — US disclosed
WO-1997044063-A2 DHA-PHARMACEUTICAL AGENT CONJUGATES NEUROMEDICA, INC. (US) 1997-11-27 — — WO disclosed
CN-1154652-A anti-dandruff composition PROCTER & GAMBLE (US) 1997-07-16 — — CN disclosed
WO-1997015298-A1 COMBINATION OF LTD, RECEPTOR ANTAGONISTS WITH GLUCOCORTICOSTEROIDS BAYER AKTIENGESELLSCHAFT (DE) 1997-05-01 — — WO disclosed
US-4427670-A CONTAINING CORTICOSTEROID, PHOSPHATIDE, AND BUTYLHYDROXYANISOLE, OR BUTYLHYDROXYTOLUENE MITSUBISHI CHEMICAL INDUSTRIES LIMITED (JP) 1984-01-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230108050-A1 CXCL8 (INTERLEUKIN-8) ACTIVITY INHIBITOR AND CORTICOSTEROID COMBINATION AND PHARMACEUTICAL COMPOSITION AND USE THEREOF CXCL8, CCR8, MMP8 PGR 2508/4885HIF1A 2536/4885AR 1822/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.